Asset Details
Do you wish to reserve the book?
PRAME expression in fibrosarcomatous dermatofibrosarcoma protuberans
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
PRAME expression in fibrosarcomatous dermatofibrosarcoma protuberans
Do you wish to request the book?
PRAME expression in fibrosarcomatous dermatofibrosarcoma protuberans
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
PRAME expression in fibrosarcomatous dermatofibrosarcoma protuberans
2024
Overview
PRAME (PReferentially expressed Antigen in MElanoma) was first identified as a malignant melanoma-specific antigen. Recently, a few cases of fibrosarcomatous dermatofibrosarcoma protuberans (FS-DFSP) were shown to have positivity for PRAME, while conventional dermatofibrosarcoma protuberans (C-DFSP) was negative. Because PRAME may be of diagnostic utility in FS-DFSP and is raising expectations as a new immunotherapy target, we examined the positivity of PRAME in FS-DFSP. Twenty-one cases of FS-DFSP and age/sex/location-matched cases of C-DFSP as a control group were examined by immunohistochemistry for CD34 and PRAME. The results were then evaluated by H-score, which was objectively and semi-quantitatively calculated using the open-source bioimaging analysis software QuPath. The results revealed that the PRAME H-score in FS-DFSP was significantly higher than that in C-DFSP (
p
= 0.0137). As for CD34, the H-score in FS-DFSP was significantly lower than that in C-DFSP (
p
< 0.001). Using these two immunohistochemical analyses in combination, the sensitivity and specificity for the diagnosis of FS-DFSP were 86% and 90%, respectively. Double staining of CD34 and PRAME revealed that PRAME-positive and CD34-positive areas did not overlap. This is the largest study to examine PRAME expression in FS-DFSP, and it confirmed the usefulness of PRAME in diagnosing this condition.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ Adult
/ Aged
/ Antigens
/ Antigens, Neoplasm - genetics
/ Antigens, Neoplasm - metabolism
/ Biomarkers, Tumor - metabolism
/ CD34
/ Dermatofibrosarcoma - diagnosis
/ Dermatofibrosarcoma - genetics
/ Dermatofibrosarcoma - metabolism
/ Dermatofibrosarcoma - pathology
/ Dermatofibrosarcoma protuberans
/ Female
/ Fibrosarcomatous dermatofibrosarcoma protuberans
/ Humanities and Social Sciences
/ Humans
/ Male
/ Melanoma
/ PRAME
/ QuPath
/ Science
